Quality of Life in the First Year after Ischemic Stroke Treated with Acute Revascularization Therapy
- PMID: 35683624
- PMCID: PMC9181285
- DOI: 10.3390/jcm11113240
Quality of Life in the First Year after Ischemic Stroke Treated with Acute Revascularization Therapy
Abstract
(1) Background: we aimed to describe the disease-specific quality of life (QoL) of ischemic stroke patients treated with acute revascularization therapy, its evolution from 6 months to 12 months, and associated factors. (2) Methods: QoL was assessed with the SS-QoL in consecutive patients treated with either intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT). Variables associated with QoL scores and its evolution were studied using multivariate mixed models, and interaction with time. Analyses were performed in four domains of SS-QoL: self-care, mobility, mood, and social roles. (3) Results: Among the 501 included patients (mean (sd) age 68.9 (14.5), 49% women), lower post-stroke QoL was independently related to lower level of school education, prestroke mRS > 2, and 24 h NIHSS score > 4. Independent predictors of unfavorable evolution of QoL over time were age <75 years (Mobility p = 0.0194 and Mood p = 0.0015), NIHSS score ≤ 4, (Self-care p = 0.0053 and Mood p = 0.0048), and modified Rankin Scale score ≤ 2 (Social roles, p = 0.0006). Revascularization therapy had no significant effect on the QoL scores, but patients treated with MT (alone or as bridging therapy) had significantly greater improvement in mobility score between 6 and 12 months than patients treated with IVT alone (p = 0.0072). (4) Conclusion: QoL evolution over one year had only slight variation and was associated with the modalities of acute treatment, age, and stroke severity.
Keywords: acute ischemic stroke; mechanical thrombectomy; patient reported outcomes; quality of life; revascularization therapy; thrombolysis.
Conflict of interest statement
Yannick Béjot reports personal fees from BMS, Pfizer, Medtronic, Amgen, Servier, Boehringer-Ingelheim, and NovoNordisk outside the submitted work. Hervé Devilliers reports personal fees from GSK and Janssens, outside the submitted work. Other authors: none.
Figures
References
-
- Rosso C., Blanc R., Ly J., Samson Y., Lehéricy S., Gory B., Marnat G., Mazighi M., Consoli A., Labreuche J., et al. Impact of Infarct Location on Functional Outcome Following Endovascular Therapy for Stroke. J. Neurol. Neurosurg. Psychiatry. 2019;90:313–319. doi: 10.1136/jnnp-2018-318869. - DOI - PubMed
-
- Froehler M.T., Saver J.L., Zaidat O.O., Jahan R., Aziz-Sultan M.A., Klucznik R.P., Haussen D.C., Hellinger F.R., Jr., Yavagal D.R., Yao T.L., et al. Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) Circulation. 2017;136:2311–2321. doi: 10.1161/CIRCULATIONAHA.117.028920. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
